Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Esteban Zavaleta-Monestel has a total of 363 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmaceutical Indication and Pharmacist Prescribing in Primary Care: An International Comparative Characterization of Regulatory Models, Clinical Scope, and Evidence Synthesis

    by Esteban Zavaleta-Monestel, Luis Carlos Monge-Bogantes, Andreina Hernandez-Cordonero, Kevin Cruz-Mora, Sofia Segura-Cano, Yajaira Quesada-Rojas, José Gatgens-Gomez, Sebastian Arguedas-Chacón, José Andrés Castro-Gamboa, Jeaustin Mora-Jiménez

    Pharmaceutical indication and pharmacist prescribing are distinct mechanisms through which community pharmacists can contribute to primary care, particularly in managing minor symptoms and low-complexity conditions. This narrative review critically compared scientific, regulatory, and institutional sources identified through PubMed/MEDLINE, ScienceDirect, Google Scholar, and consultation of regulatory and professional documents. Domains of the Scale for the Assessment of Narrative Review Articles (SANRA) informed appraisal of the manuscript, rather than source selection or assessment of individual studies. Four recurrent analytical configurations were identified: pharmaceutical indication, protocol-based medicine supply or prescribing, collaborative prescribing, and independent prescribing. Their legal bases, clinical scopes, medicine-access mechanisms, and implementation requirements differ between and within jurisdictions. In the examples reviewed, structured services variously specify eligibility criteria, red-flag assessment, safety-netting, referral, documentation, and coordination with other healthcare professionals. Heterogeneous study designs and outcome measures limit comparisons of clinical effectiveness, safety, service utilization, and costs; no universal hierarchy among regulatory configurations can be established. In selected Latin American settings, including Costa Rica, pharmaceutical consultation and indication are documented, although formalization varies. Future research should prioritize comparable definitions, standardized outcomes, and sustainability.

  • Open Access

    Decalogue of Ibero-American Community Pharmacy: Declaration of Abarán, Spain

    by Jesús Carlos Gómez-Martínez, Miguel A. Gastelurrutia, Karen Orellana-Reyes, Aldana Intilangelo, Carlos Maurício Barbosa, Lucrecia Martínez de Haase, Rinaldo Ferreira, Alexis Morales, Anne Liere-Godoy, Carolina Mosca, et al.

    Introduction: It is well known that community pharmacy in Latin America exhibits conceptual, regulatory and care-related heterogeneity, making it difficult to integrate community pharmacists into health systems in a uniform manner. The objective of this study was to present the Decalogue of Ibero-American Community Pharmacy, developed by the Scientific-Professional Society of Ibero-American Community Pharmacy (SOCFIC by its Spanish acronym), and its operationalization as a preliminary tool to evaluate regional development, identify and prioritize gaps, establish levels of maturity, and guide public policies, national plans, and strengthening strategies. Method: A methodological study was carried out in two stages: development and validation of the Decalogue by experts from 17 Ibero-American countries, and its operationalization through a matrix of indicators, categories of compliance, and progressive levels of maturity. Results: The Decalogue of Ibero-American Community Pharmacy was developed along with a preliminary Evaluation Matrix, four levels of maturity, and an implementation roadmap focused on monitoring, comparison, and regional strengthening. Conclusions: The Decalogue and its operationalization provide a common framework for evaluating, monitoring, and guiding policies and strategies to strengthen Ibero-American community pharmacies.

  • Open Access

    Long-Term Cardiovascular Safety of Melatonin: Why Dose, Duration, and Patient Phenotype Matter

    by Esteban Zavaleta-Monestel, José A Castro Gamboa, Kevin Cruz Mora, Jeaustin Mora-Jiménez

    The long-term cardiovascular safety of melatonin remains an important area of clinical uncertainty. This editorial examines the challenges involved in evaluating cardiovascular risk associated with prolonged melatonin exposure, emphasizing the importance of dose, treatment duration, formulation, product quality, and patient characteristics. Particular attention is given to methodological limitations that complicate the interpretation of observational associations, including residual confounding, reverse causation, and exposure misclassification. The discussion also considers potential biological mechanisms while distinguishing mechanistic hypotheses from established causal relationships. A more comprehensive approach to cardiovascular safety assessment is proposed, incorporating precise exposure characterization, clinically relevant cardiovascular outcomes, and patient phenotyping. Future research should integrate these factors through appropriately designed clinical trials and observational studies to clarify the cardiovascular implications of long-term melatonin use. Until stronger evidence becomes available, clinical interpretation should acknowledge the remaining uncertainty rather than assuming either cardiovascular safety or harm.

  • Open Access

    Comparative Cardiac Adverse-Event Reporting Patterns Across Antineoplastic Therapeutic Classes: A Global Analysis Using WHO VigiAccess

    by Esteban Zavaleta-Monestel, Jeaustin Mora-Jiménez, Jorge Arturo Villalobos-Madriz, Kevin Tencio-Morales, Brandon Enríquez-Gutiérrez, José Andrés Castro Gamboa, Sebastián Arguedas-Chacón

    Background/Objectives: Cardiac adverse-event reports for antineoplastic agents may differ across regulatory coding categories, affecting disproportionality estimates. We compared anthracyclines, human epidermal growth factor receptor 2 (HER2)-targeted agents, and vascular endothelial growth factor (VEGF) inhibitors. Methods: We analyzed aggregated World Health Organization VigiAccess data retrieved on March 23, 2026, for eight drugs in three classes. Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class and cardiac Preferred Term distributions were described; reporting odds ratios (RORs) with 95% confidence intervals (CIs) were calculated using a restricted antineoplastic comparator cohort. Pairwise within-cohort comparators and cardiac/vascular outcomes were explored; an external database-wide comparison was not feasible. Results: Across 389,068 drug-specific report observations, anti-HER2 agents had the highest proportion classified under Cardiac disorders (10.43%) and the strongest class-level ROR (2.04; 95% CI 1.99–2.10); trastuzumab had the highest drug-level ROR (2.22; 2.16–2.29). Anthracyclines contributed the most cardiac reports (11,273), whereas anti-VEGF agents showed greater proportional reporting in vascular disorders (10.86%) and prominent myocardial infarction reports among cardiac Preferred Terms. Exploratory analyses demonstrated sensitivity to comparator composition and outcome definition. Conclusions: Reporting patterns varied across classes, but these findings do not establish incidence, causality, comparative clinical risk, or independent grounds for changing surveillance protocols.

  • Open Access

    Pharmaceutical Indication and Pharmacist Prescribing in Primary Care: An International Comparative Characterization of Regulatory Models, Clinical Scope, and Evidence Synthesis

    by Esteban Zavaleta-Monestel, Luis Carlos Monge-Bogantes, Andreina Hernandez-Cordonero, Kevin Cruz-Mora, Sofia Segura-Cano, Yajaira Quesada-Rojas, Jose Gatgens-Gomez, Sebastian Arguedas-Chacón, José Andrés Castro-Gamboa, Jeaustin Mora-Jiménez

    Pharmaceutical indication and pharmacist prescribing have become strategies for expanding the capacity of primary care, particularly in the management of minor symptoms and low-complexity clinical conditions. This narrative review, guided by the SANRA domains, integrated scientific, regulatory, and institutional evidence identified through PubMed/MEDLINE, ScienceDirect, and Google Scholar, supplemented by grey literature from regulatory bodies, health services, and professional organizations, to comparatively characterize regulatory and practice models described across jurisdictions. Four main configurations were identified: pharmaceutical indication, protocol-based models, collaborative prescribing, and independent prescribing, with heterogeneous implementation internationally. Available evidence reports favorable outcomes in some services, including improved accessibility, high user satisfaction, and a potential shift in consultations from other healthcare settings to community pharmacy; however, heterogeneity in study designs, settings, and outcome measures, together with the predominance of observational and implementation studies, limits the certainty of these findings. Rather than demonstrating the superiority of a particular level of professional autonomy, the literature consistently shows that structured models incorporate clinical protocols, eligibility criteria, red-flag assessment, safety-netting, referral, and documentation. Effective implementation also requires consideration of professional training, care integration, documentation systems, and sustainable funding mechanisms. In Latin America and Costa Rica, the literature documents frequent pharmaceutical consultation and indication practices, although with variable levels of formalization and standardization.

  • Open Access

    HLA-DQ8 Predominance and HLA-DQ2/DQ8 Profile Distribution in Patients Undergoing Celiac Disease Genetic Testing in Costa Rica: A Retrospective Observational Study

    by Sebastián Arguedas-Chacón, Valeria Granados-Villalta, Karla Gutiérrez-González, José Moreno-Araya, Esteban Zavaleta-Monestel

    Background/Objectives: Celiac disease (CD) is a chronic immune-mediated disorder associated with genetic susceptibility conferred primarily by HLA-DQ2 and HLA-DQ8. Although HLA genotyping cannot confirm CD because these profiles are common in individuals without the disease, it has a complementary role in the diagnostic evaluation, particularly when compatible HLA profiles are absent. Contemporary data on the distribution of CD-associated HLA profiles in Central America remain limited. This study aimed to characterize the distribution of HLA-DQ2.2, HLA-DQ2.5, and HLA-DQ8 profiles among patients referred for CD-related genetic testing in Costa Rica and to evaluate their distribution according to biological sex and age. Methods: We retrospectively evaluated HLA-DQ2/DQ8 genotyping records from patients tested for suspected CD at Hospital Clínica Bíblica, Costa Rica, between January 2018 and August 2024. After patient-level review of 361 complete determinations from 292 unique patients, four patients with unresolved discordant repeated results were excluded, yielding a final analytical cohort of 288 patients. HLA profiles were summarized descriptively, and associations with sex and age were evaluated using Fisher’s exact test, the Mann–Whitney U test, and Pearson’s chi-square test, with Holm adjustment for multiple comparisons involving individual HLA profiles. Results: Among 288 patients, 207 (71.9%) were female, and the median age was 33 years. HLA-DQ8 was the most frequently detected CD-associated profile (31.9%; 95% CI 26.8–37.5%), whereas HLA-DQ2.2 and HLA-DQ2.5 were each detected in 19.4% (95% CI 15.3–24.4%). Overall, 59.7% of patients carried at least one of these three profiles, while 112 (38.9%; 95% CI 33.4–44.6%) had negative results for all four evaluated assay components. No statistically significant associations were identified between individual HLA profiles and biological sex after adjustment for multiple comparisons. Age did not differ according to overall HLA-profile status (p = 0.874), and HLA-profile distribution did not differ significantly across age groups (p = 0.677). Conclusions: HLA-DQ8 was the most frequently detected CD-associated HLA profile in this clinically referred Costa Rican cohort, while DQ2.2 and DQ2.5 occurred at lower and similar frequencies. No significant associations with biological sex or age were identified. These findings provide contemporary data on HLA-DQ2/DQ8 distribution in a Costa Rican clinical setting but should not be interpreted as estimates of population HLA prevalence or CD prevalence. Studies integrating HLA genotyping with clinical, serological, histological, and diagnostic outcome data are needed to establish the clinical significance of these distributions.

  • Open Access

    Private-Sector Sales Trends of Antidepressants and Antipsychotics in Costa Rica, 2022–2026: An Aggregate Analysis by Active Ingredient

    by Esteban Zavaleta-Monestel, Luis Herrera-Jiménez, Sebastian Arguedas-Chacón, Jose Castro-Gamboa, Kevin Cruz-Mora, Jeaustin Mora-Jiménez, Ricardo Millán-González

    Aggregated pharmaceutical sales data can characterize apparent medication consumption and changes in market composition, although they do not represent individual prescribing or patient exposure. This study described private-sector sales trends of antidepressants and antipsychotics in Costa Rica from moving annual total (MAT) February 2022 to MAT February 2026. An observational, descriptive, longitudinal study was conducted using aggregated IQVIA sales data. Total defined daily doses (DDDs) sold were analyzed as the primary indicator, complemented by units sold and analyses by therapeutic group and active ingredient. Antidepressant DDDs increased from 15,299,281 to 17,976,312 (+17.5%), whereas antipsychotic DDDs increased from 1,078,635 to 1,476,810 (+36.9%). In 2026, escitalopram and sertraline had the highest DDD volumes among antidepressants, while quetiapine was the leading antipsychotic. Desvenlafaxine was the largest contributor to net antidepressant growth, whereas aripiprazole and lurasidone contributed substantially to antipsychotic growth. Overall, private-sector sales of both therapeutic groups increased, with distinct patterns across active ingredients. These findings provide a baseline for pharmaceutical market surveillance but should not be interpreted as estimates of total national consumption, public-sector utilization, individual prescribing, clinical indications, or actual patient exposure.

  • Open Access

    Vaccine Dispensing Through Private Community Pharmacies in Costa Rica: A National Descriptive Analysis

    by Jeaustin Mora-Jiménez, Kevin Cruz-Mora, Sofia Segura-Cano, Yajaira Quesada-Rojas, Jose Gatgens-Gomez, Sebastian Arguedas-Chacón, Esteban Zavaleta-Monestel

    Background: Pharmacist involvement in immunization has expanded as a strategy to improve access to vaccines. In Costa Rica, private community pharmacies operate under a regulatory framework for vaccination services, yet evidence on private-market vaccine dispensing remains limited. The aim of this study was to characterize vaccine dispensing through private community pharmacies in Costa Rica by dispensed doses, economic value, vaccine category, and provincial distribution, comparing MAT February 2025 and MAT February 2026. Methods: A descriptive, retrospective, national study was conducted using an aggregated secondary IQVIA database of the Costa Rican private pharmaceutical market. Dispensed doses, economic value in USD, percentage variation, and share by vaccine category and province were analyzed; no individual patient, professional, establishment, or nominal vaccination records were used. Results: Dispensed doses increased from 162,664 to 217,387 (+33.6%), while economic value increased from USD 8,700,809 to USD 13,416,717 (+54.2%). Influenza accounted for the highest dispensing volume in MAT February 2026 (87,064 doses). Yellow fever showed the largest between-period increase, from 22,281 to 70,133 doses and from USD 2.7 million to USD 7.0 million. HPV ranked second in economic value (USD 3.6 million). San José accounted for 63.0% of dispensed doses and 52.9% of national private-market economic value. Conclusions: Private-market vaccine dispensing through Costa Rican community pharmacies was higher in MAT February 2026 than in MAT February 2025 in both dispensed doses and economic value, driven primarily by yellow fever. Influenza accounted for the highest dispensing volume, while HPV retained substantial economic weight. These findings characterize vaccine dispensing through the private community pharmacy market but do not establish vaccine administration, vaccination coverage, or clinical or epidemiological outcomes.

  • Infección urinaria febril por Escherichia coli productora de betalactamasa de espectro extendido (BLEE) en una lactante con fracaso del tratamiento empírico

    by Jorge Martinez Vasquez, Jeaustin Mora Jiménez, Kevin Cruz Mora, Esteban Zavaleta Monestel

    Las infecciones urinarias febriles causadas por enterobacterias productoras de betalactamasa de espectro extendido (BLEE) representan un desafío creciente en pediatría debido al incremento de la resistencia antimicrobiana y al riesgo de fracaso del tratamiento empírico.